Lesions solely involving intertriginous areas, the scalp or the face

Systemic therapy for their psoriasis

Pustular psoriasis or erythroderma

Currently on other topical agents or Ultraviolet B (UVB) therapy within 2 weeks of the first dose of study medication

Started or discontinued therapy within 2 months of Screening with agents that can exacerbate psoriasis

Receiving systemic triazole antifungals except fluconazole

A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis